Is 5q deletion in de novo Acute Myelogenous Leukemia (AML) with excess blasts a surrogate marker for the cryptic t(7;21)(p22;q22)? A case report and review of literature

Cancer Genet. 2022 Apr:262-263:30-34. doi: 10.1016/j.cancergen.2021.12.008. Epub 2021 Dec 24.

Abstract

Although the 5q- syndrome is common in both de novo and treatment related myelodysplastic syndrome (MDS) and the World Health Organization defined 5q- syndrome as a specific type of MDS, it is less common in acute myelogenous leukemia (AML). Recently, it was suggested that AML with diploidy/tetraploidy and/or 5q alterations may be associated with the cryptic translocation, t(7;21)(p22;q22) resulting in RUNX1-USP42 gene fusion and this association may have been underestimated. Here, we report another case of de novo AML with cryptic t(7;21)(p22;q22) associated with a 5q deletion.

Keywords: 5q abnormalities; Acute myeloid leukemia; Fluorescence in situ hybridization; Minimal differentiation; t(7, 21).

Publication types

  • Case Reports
  • Review

MeSH terms

  • Anemia, Macrocytic
  • Biomarkers
  • Chromosome Aberrations
  • Chromosome Deletion
  • Chromosomes, Human, Pair 5
  • Cri-du-Chat Syndrome
  • Humans
  • In Situ Hybridization, Fluorescence
  • Leukemia, Myeloid, Acute* / genetics
  • Myelodysplastic Syndromes* / genetics
  • Translocation, Genetic
  • Trisomy

Substances

  • Biomarkers

Supplementary concepts

  • Chromosome 5, trisomy 5q
  • Chromosome 5q Deletion Syndrome